Takeda has been fined $6bn over alleged health risks of its Actos diabetes treatment. Eli Lilly, its US partner, must pay $3bn. Lex's Oliver Ralph and Robert Armstrong discuss whether the drugs companies can recover from such hefty penalties.
For more video content from the Financial Times, visit http://www.FT.com/video
Subscribe to the Financial Times on YouTube; http://goo.gl/vUQx5k
Twitter https://twitter.com/ftvideo
Facebook https://www.facebook.com/financialtimes
